Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- RAD.AU
- Price
- 0.02
- Stock movement down
- -0.00 (-17.39%)
- Company name
- Radiopharm Theranostics Ltd
- Exchange
- (AU ,
- Currency
- AUD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 41.29M
- Ent value
- 67.39M
- Price/Sales
- 21.08
- Price/Book
- 1.51
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -62.75%
- 3 year return
- -55.46%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-08
DIVIDENDS
RAD.AU does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 21.08 |
| Price to Book | 1.51 |
| EV to Sales | 34.41 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 2.17B |
| EPS (TTM) | -0.20 |
| FCF per share (TTM) | -0.08 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.96M |
| Gross profit (TTM) | -13.67M |
| Operating income (TTM) | -63.28M |
| Net income (TTM) | -71.92M |
| EPS (TTM) | -0.20 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -697.90% |
| Operating margin (TTM) | -3231.22% |
| Profit margin (TTM) | -3672.34% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 18.58M |
| Net receivables | 987.41K |
| Total current assets | 22.85M |
| Goodwill | 0.00 |
| Intangible assets | 49.09M |
| Property, plant and equipment | 60.80K |
| Total assets | 72.04M |
| Accounts payable | 6.43M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 17.58M |
| Total liabilities | 44.68M |
| Shareholder's equity | 27.35M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -28.86M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -28.86M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -262.94% |
| Return on Assets | -99.84% |
| Return on Invested Capital | -262.94% |
| Cash Return on Invested Capital | -105.52% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.02 |
| Daily high | 0.02 |
| Daily low | 0.02 |
| Daily Volume | 9.86M |
| All-time high | 0.40 |
| 1y analyst estimate | 0.24 |
| Beta | 0.85 |
| EPS (TTM) | -0.20 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 15 Apr 2025 |
Downside potential
Loading...
Downside potential data
| RAD.AU | S&P500 | |
| Current price drop from All-time high | -95.19% | -17.71% |
| Highest price drop | -95.19% | -56.47% |
| Date of highest drop | 7 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -69.03% | -11.07% |
| Avg time to new high | 121 days | 12 days |
| Max time to new high | 825 days | 1805 days |
COMPANY DETAILS
Marketcap
41.29M
Marketcap category
Small-cap
Description
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. The company was incorporated in 2021 and is based in Carlton, Australia.
Employees
0
Investor relations
-
SEC filings
CEO
Country
Australia
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found